// App-Quantinova.ai

840 : Lactobacillus Casei Shirota (LCS; Yakult) vs Placebo in patients with well‐compensated cirrhosis: A double‐blind, randomized controlled study

Researchers

Presenter

  • Jane Macnauahtan

Principal Investigators

  • Elisabet Garca Lopez

  • Winston Lu

  • Helen Jones

  • Rohit Sawhney

  • Joanne Marsden

  • Nathan Davies

  • I. Jane Cox

  • Gavin Wright

  • Linda Thomas

  • Rajeshwar Mookerjee

  • Rajiv Jalan

Medical Centers

  • Kings College London, London, United Kingdom

  • EF‐CLIF, Barcelona, Spain

  • Kings College London, London, United Kingdom

  • The Institute of Hepatology, London, United Kingdom

  • Basildon and Thurrock University Hospitals NHS Foundation Trust, Basildon, United Kingdom

  • Yakult GB, Middlesex, United Kingdom

Locations

  • United Kingdom

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Systemic inflammation

  • Cirrhosis

Biomarkers

  • Proto-oncogene tyrosine-protein kinase ROS

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved